Allos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009 |
 |
 |
| Wednesday, 22 July 2009 07:09 |
|
The webcast of this call will be available from the homepage and the investors/media section of the Company's Web site, www.allos.com. Alternatively, callers may participate in the conference call by dialing 888-549-7880 (domestic) or 480-629-9869 (international). Participants should reference the Allos Therapeutics conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, August 14, 2009. To access the replay, callers should dial 1-800-406-7325 (domestic) or 303-590-3030 (international) and use passcode 4117858#. About Allos Therapeutics, Inc. Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. The Company’s product candidate, pralatrexate, is a selective antifolate designed to accumulate preferentially in cancer cells. The Company recently announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for pralatrexate for patients with relapsed or refractory peripheral T-cell lymphoma for priority review and established a Prescription Drug User Fee Act date of September 24, 2009 for a decision regarding approval of the NDA. In addition, pralatrexate is being evaluated in patients with non-small cell lung cancer, bladder cancer and a range of lymphoma sub-types. Allos retains exclusive worldwide rights to pralatrexate for all indications. The Company is headquartered in Westminster, Colo. For more information about Allos, visit www.allos.com. BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
WESTMINSTER, Colo.--Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that Company management will provide a corporate update and review of the second quarter 2009 results via webcast and conference call on Tuesday, August 4, 2009, at 4:30 p.m. ET.
Free Phone Trade Alerts
